Literature DB >> 11981799

Contemporary treatment of thrombosed hemodialysis grafts.

D T Gibbens1, J Triolo, T Yu, J Depalma, J Iglasias, D Castner.   

Abstract

Maintaining hemodialysis grafts remains a difficult problem. Before the early 1990s, graft declotting was usually performed in the surgical suite. Percutaneous declotting has been evolving since the mid-1980s. Initially, a low-dose thrombolytic infusion of streptokinase through a single catheter was used. Crossing catheters with a higher-dose infusion of urokinase was then introduced. This technique was modified with the adjunctive use of pharmacomechanical techniques with the use of compliant balloons and the adjunctive use of heparin. The advent of the "lyse-and-wait" technique provided a simpler and quicker way to declot thrombosed grafts by using urokinase, with similar outcomes. Since the removal of urokinase from the market, multiple mechanical devices have been used with similar success. Recent reports concerning the use of newer-generation thrombolytic agents report similar outcomes, with a reduction in total cost. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11981799     DOI: 10.1016/s1089-2516(01)90007-1

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  3 in total

1.  Delayed presentation of rupture after venous angioplasty.

Authors:  Matthew Backer; Steven Zangan
Journal:  Semin Intervent Radiol       Date:  2007-09       Impact factor: 1.513

2.  Endovascular Declotting of Wall-Adherent Thrombi in Hemodialysis Vascular Access.

Authors:  Chih-Wei Hung; Chao-Lun Lai; Mu-Yang Hsieh; Ruei-Cheng Kuo; Kuei-Chin Tsai; Lin Lin; Chih-Cheng Wu
Journal:  Acta Cardiol Sin       Date:  2014-03       Impact factor: 2.672

3.  Percutaneous treatment of failed native dialysis fistulas: use of pulse-spray pharmacomechanical thrombolysis as the primary mode of therapy.

Authors:  Sung Ki Cho; Heon Han; Sam Soo Kim; Ji Yeon Lee; Sung Wook Shin; Young Soo Do; Kwang Bo Park; Sung Wook Choo; In-Wook Choo
Journal:  Korean J Radiol       Date:  2006 Jul-Sep       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.